RS51211B - Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja - Google Patents

Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja

Info

Publication number
RS51211B
RS51211B RSP-2010/0089A RSP20100089A RS51211B RS 51211 B RS51211 B RS 51211B RS P20100089 A RSP20100089 A RS P20100089A RS 51211 B RS51211 B RS 51211B
Authority
RS
Serbia
Prior art keywords
treatment
opioid receptor
receptor antagonists
containing compositions
kappa opioid
Prior art date
Application number
RSP-2010/0089A
Other languages
English (en)
Inventor
Lars-Holger Dr. Hermann
Original Assignee
Emodis Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodis Gmbh. filed Critical Emodis Gmbh.
Publication of RS51211B publication Critical patent/RS51211B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Primena jedne formulacije, koja obuhvata kapa-opioid rezeptor-antagoniste sa formulom koja sledi, za proizvodnju medikamenata za tretman poremećaja emocionalno nestabilnih ličnosti (F60.3 der ICD- 10) kod ljudi:ili njihovih farmaceutski prihvatljivih soli, estara, etara i / ili hidrida.Prijava sadrži još 2 zavisna patentna zahteva.
RSP-2010/0089A 2006-04-04 2007-04-03 Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja RS51211B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
PCT/EP2007/053248 WO2007115975A2 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
RS51211B true RS51211B (sr) 2010-12-31

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0089A RS51211B (sr) 2006-04-04 2007-04-03 Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja

Country Status (17)

Country Link
US (1) US8063059B2 (sr)
EP (1) EP2001456B1 (sr)
JP (1) JP5128578B2 (sr)
AT (1) ATE450256T1 (sr)
AU (1) AU2007236003B2 (sr)
CA (1) CA2646899C (sr)
CY (1) CY1109862T1 (sr)
DE (1) DE502007002185D1 (sr)
DK (1) DK2001456T3 (sr)
EA (1) EA014820B1 (sr)
ES (1) ES2337622T3 (sr)
HR (1) HRP20100113T1 (sr)
PL (1) PL2001456T3 (sr)
PT (1) PT2001456E (sr)
RS (1) RS51211B (sr)
SI (1) SI2001456T1 (sr)
WO (1) WO2007115975A2 (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2388708T3 (es) 2008-01-22 2012-10-17 Eli Lilly And Company Antagonista selectivo del receptor opioide kappa
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CA2933733A1 (en) * 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
ME02946B (me) 2014-04-28 2018-04-20 Orphomed Inc Dimer buprenorfina i njegova upotreba u lecenju gastrointestinalnih poremecaja
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US20220370409A1 (en) 2021-05-04 2022-11-24 Janssen Pharmaceuticals, Inc. Compositions And Methods For The Treatment Of Depression
TW202345796A (zh) 2022-03-07 2023-12-01 美商健生醫藥公司 阿替卡普蘭（ａｔｉｃａｐｒａｎｔ）之形式

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
WO1999045906A1 (en) * 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
EP1365756A2 (en) * 2000-08-15 2003-12-03 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US20020045572A1 (en) * 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7268151B2 (en) * 2003-04-04 2007-09-11 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
BRPI0508254A (pt) * 2004-03-02 2007-07-24 Pharmacia Corp métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
US7423144B2 (en) * 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
EP1750675B1 (en) 2004-06-02 2008-10-29 Galephar M/F Stable oral pharmaceutical compositions of buprenorphine and salt thereof

Also Published As

Publication number Publication date
EP2001456B1 (de) 2009-12-02
CA2646899A1 (en) 2007-10-18
EA200802104A1 (ru) 2009-04-28
EA014820B1 (ru) 2011-02-28
CA2646899C (en) 2014-05-06
HRP20100113T1 (hr) 2010-04-30
EP2001456A2 (de) 2008-12-17
JP5128578B2 (ja) 2013-01-23
WO2007115975A2 (de) 2007-10-18
US20090181999A1 (en) 2009-07-16
WO2007115975A3 (de) 2008-02-14
PT2001456E (pt) 2010-03-03
AU2007236003B2 (en) 2012-10-18
AU2007236003A1 (en) 2007-10-18
ATE450256T1 (de) 2009-12-15
DE502007002185D1 (de) 2010-01-14
US8063059B2 (en) 2011-11-22
CY1109862T1 (el) 2014-09-10
SI2001456T1 (sl) 2010-04-30
DK2001456T3 (da) 2010-04-12
JP2009532434A (ja) 2009-09-10
PL2001456T3 (pl) 2010-05-31
ES2337622T3 (es) 2010-04-27

Similar Documents

Publication Publication Date Title
RS51211B (sr) Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2007004699A (es) Derivados de indol y bencimidazol.
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
JO3021B1 (ar) احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
NO20083630L (no) Nye pyridinderivater
WO2009102893A3 (en) Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors
JP2009506080A5 (sr)
GEP20125389B (en) Substituted pyrazole and triazole compounds as ksp inhibitors
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX352516B (es) Compuestos terapeuticos.
GEP20125415B (en) Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
RS53586B1 (sr) Derivati deoksiaktagardina
UA96277C2 (en) Benzimidazole derivatives
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
MX365313B (es) Composición farmacéutica oral que comprende a,a,a-trifluorotimidin a y clorhidrato de 5-cloro-6-(2-iminopirrolidina-1-il)metil-2,4(1h ,3h)-pirimidina diona.
IL192949A0 (en) Kinase inhibitors and methods of use thereof